|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-3-15
|
|
pubmed:abstractText |
Tumor-infiltrating cytotoxic T lymphocytes (TILs), including CD8 TILs, have been associated with favorable clinical outcomes in multiple tumor types. Tumor-infiltrating CD8 T cells and major histocompatibility complex (MHC) class I expression in urothelial carcinoma (UC) have not been previously reported. Most immune responses are mediated by local cytotoxic lymphocytes (CD8 T cells), which can eradicate tumor cells by recognizing tumor-associated antigens presented by MHC class I molecules. Here we analyzed the presence of intratumoral CD8 T cells, the expression of MHC class I antigen, and the expression of the NY-ESO-1 tumor antigen in UC samples and correlated our findings with clinical outcome. Immunohistochemical staining for intratumoral CD8 T cells in tissue samples from 69 patients with UC showed that patients with advanced UC (pT2, pT3, or pT4) and higher numbers of CD8 TILs within the tumor (> or =8) had better disease-free survival (P < 0.001) and overall survival (P = 0.018) than did patients with similar-staged UC and fewer intratumoral CD8 TILs. We conclude that the extent of intratumoral CD8 TILs is an important prognostic indicator in advanced UC.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-10188055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-10335805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-11205913,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-11358808,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-11431351,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-11489802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-11556981,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-118884,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-11920606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-12529460,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-12538675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-14680360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-14738373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-15191035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-15252201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-15494715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-16034368,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-16344461,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-17000678,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-17008531,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-1840703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-2088481,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-8524854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-9190110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17360461-9721846
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
pubmed-author:BajorinDean FDF,
pubmed-author:GnjaticSachaS,
pubmed-author:HerrHarryH,
pubmed-author:JungbluthAchim AAA,
pubmed-author:OldLloyd JLJ,
pubmed-author:ReuterVictor EVE,
pubmed-author:SatoEiichiE,
pubmed-author:SharmaPadmaneeP,
pubmed-author:ShenYuY,
pubmed-author:WenSijinS,
pubmed-author:YamadaSachikoS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
6
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3967-72
|
|
pubmed:dateRevised |
2010-9-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17360461-Antigens, CD8,
pubmed-meshheading:17360461-Antigens, Neoplasm,
pubmed-meshheading:17360461-CD8-Positive T-Lymphocytes,
pubmed-meshheading:17360461-Carcinoma,
pubmed-meshheading:17360461-Cell Line, Tumor,
pubmed-meshheading:17360461-Disease-Free Survival,
pubmed-meshheading:17360461-Female,
pubmed-meshheading:17360461-Genes, MHC Class I,
pubmed-meshheading:17360461-Humans,
pubmed-meshheading:17360461-Immunohistochemistry,
pubmed-meshheading:17360461-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:17360461-Male,
pubmed-meshheading:17360461-Muscles,
pubmed-meshheading:17360461-Prognosis,
pubmed-meshheading:17360461-Treatment Outcome,
pubmed-meshheading:17360461-Urinary Bladder Neoplasms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.
|
|
pubmed:affiliation |
Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. padsharma@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
